Applied Therapeutics Inc
2UV
Company Profile
Business description
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Contact
545 Fifth Avenue
Suite 1400
New YorkNY10017
USAT: +1 212 220-9226
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
stocks
Apple earnings: Strong performance overpowers headwinds, and we raise our FVE
Our view of Apple shares.
stocks
Coles is winning the supermarket wars but is Woollies the better long-term opportunity?
Our view after first quarter sales updates.
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.70 | 8.80 | -0.10% |
| CAC 40 | 8,121.07 | 79.81 | -0.97% |
| DAX 40 | 23,958.30 | 160.59 | -0.67% |
| Dow JONES (US) | 47,562.87 | 40.75 | 0.09% |
| FTSE 100 | 9,717.25 | 42.81 | -0.44% |
| HKSE | 25,906.65 | 376.04 | -1.43% |
| NASDAQ | 23,724.96 | 143.81 | 0.61% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,540.91 | 7.41 | -0.05% |
| S&P 500 | 6,840.20 | 17.86 | 0.26% |
| S&P/ASX 200 | 8,852.20 | 6.40 | -0.07% |
| SSE Composite Index | 3,954.79 | 0.00 | -0.00% |